United Therapeutics Corp (NASDAQ:UTHR) Institutional Investors Quarterly Sentiment

December 13, 2017 - By Hazel Jackson

 United Therapeutics Corp (NASDAQ:UTHR) Institutional Investors Quarterly Sentiment

Sentiment for United Therapeutics Corp (NASDAQ:UTHR)

United Therapeutics Corp (NASDAQ:UTHR) institutional sentiment decreased to 1.03 in Q2 2017. Its down -0.22, from 1.25 in 2017Q1. The ratio fall, as 165 institutional investors increased or started new stock positions, while 160 sold and reduced their positions in United Therapeutics Corp. The institutional investors in our partner’s database now possess: 44.22 million shares, down from 45.90 million shares in 2017Q1. Also, the number of institutional investors holding United Therapeutics Corp in their top 10 stock positions decreased from 4 to 3 for a decrease of 1. Sold All: 54 Reduced: 106 Increased: 125 New Position: 40.

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company has market cap of $5.89 billion. The companyÂ’s product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It has a 12.1 P/E ratio. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy.

The stock increased 0.81% or $1.09 during the last trading session, reaching $136.31. About 141,184 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has risen 9.78% since December 13, 2016 and is uptrending. It has underperformed by 6.92% the S&P500.

Analysts await United Therapeutics Corporation (NASDAQ:UTHR) to report earnings on February, 28. They expect $3.41 earnings per share, up 29.17 % or $0.77 from last year’s $2.64 per share. UTHR’s profit will be $147.35 million for 9.99 P/E if the $3.41 EPS becomes a reality. After $6.27 actual earnings per share reported by United Therapeutics Corporation for the previous quarter, Wall Street now forecasts -45.61 % negative EPS growth.

Palo Alto Investors Llc holds 11.31% of its portfolio in United Therapeutics Corporation for 1.87 million shares. Krensavage Asset Management Llc owns 272,996 shares or 10.75% of their US portfolio. Moreover, Argentiere Capital Ag has 3.39% invested in the company for 77,957 shares. The Connecticut-based Dock Street Asset Management Inc has invested 2.14% in the stock. Evanston Investments Inc. Dba Evanston Advisors, a Illinois-based fund reported 55,283 shares.#img1#

Since January 1, 0001, it had 0 insider buys, and 15 selling transactions for $2.30 million activity.

United Therapeutics Corporation (NASDAQ:UTHR) Ratings Coverage

Ratings analysis reveals 17% of United Therapeutics’s analysts are positive. Out of 12 Wall Street analysts rating United Therapeutics, 2 give it “Buy”, 4 “Sell” rating, while 6 recommend “Hold”. The lowest target is $95.0 while the high is $244. The stock’s average target of $149.89 is 9.96% above today’s ($136.31) share price. UTHR was included in 25 notes of analysts from July 29, 2015. The stock of United Therapeutics Corporation (NASDAQ:UTHR) has “Sell” rating given on Thursday, September 14 by Jefferies. The stock of United Therapeutics Corporation (NASDAQ:UTHR) has “Sell” rating given on Tuesday, June 6 by Jefferies. The rating was maintained by H.C. Wainwright on Thursday, October 26 with “Hold”. The rating was downgraded by Barclays Capital to “Underweight” on Tuesday, November 29. The stock of United Therapeutics Corporation (NASDAQ:UTHR) earned “Buy” rating by Argus Research on Friday, July 31. The firm earned “Hold” rating on Thursday, January 19 by Standpoint Research. Cowen & Co maintained the shares of UTHR in report on Thursday, October 26 with “Hold” rating. Oppenheimer maintained United Therapeutics Corporation (NASDAQ:UTHR) rating on Sunday, July 30. Oppenheimer has “Buy” rating and $17500 target. The stock of United Therapeutics Corporation (NASDAQ:UTHR) earned “Buy” rating by Wedbush on Monday, November 13. Argus Research downgraded the stock to “Hold” rating in Tuesday, May 24 report.

More notable recent United Therapeutics Corporation (NASDAQ:UTHR) news were published by: Streetinsider.com which released: “SteadyMed Ltd. (STDY) Reports Invalidation of United Therapeutics (UTHR) ‘393 …” on November 14, 2017, also Seekingalpha.com with their article: “United Therapeutics Stock May Bottom Out After Strong Q3 Results” published on November 23, 2017, Prnewswire.com published: “United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity …” on November 20, 2017. More interesting news about United Therapeutics Corporation (NASDAQ:UTHR) were released by: Streetinsider.com and their article: “United Therapeutics Corp. (UTHR) PT Raised to $102 at UBS; ‘Adcirca Generics …” published on November 21, 2017 as well as Bizjournals.com‘s news article titled: “United Therapeutics gets much-needed reprieve with drug patent” with publication date: November 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: